Concept information
Preferred term
Alendronate
Type
-
mesh:Descriptor
Definition
- A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.
Broader concept
Entry terms
- 121268-17-5 (mono-Na salt, trihydrate)
- 2UY4M2U3RA
- 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate
- 66376-36-1 (Alendronate)
- Aminohydroxybutane Bisphosphonate
- X1J18R4W8P
Allowable Qualifier(s)
- administration & dosage (Qualifier)
- adverse effects (Qualifier)
- agonists (Qualifier)
- analogs & derivatives (Qualifier)
- analysis (Qualifier)
- antagonists & inhibitors (Qualifier)
- blood (Qualifier)
- cerebrospinal fluid (Qualifier)
- chemical synthesis (Qualifier)
- chemistry (Qualifier)
- classification (Qualifier)
- economics (Qualifier)
- history (Qualifier)
- immunology (Qualifier)
- isolation & purification (Qualifier)
- metabolism (Qualifier)
- pharmacokinetics (Qualifier)
- pharmacology (Qualifier)
- poisoning (Qualifier)
- radiation effects (Qualifier)
- standards (Qualifier)
- supply & distribution (Qualifier)
- therapeutic use (Qualifier)
- toxicity (Qualifier)
- urine (Qualifier)
Pharmacological Action(s)
In other languages
-
French
-
121268-17-5 (mono-Na salt, trihydrate)
-
2UY4M2U3RA
-
66376-36-1 (Alendronate)
-
X1J18R4W8P
URI
http://data.loterre.fr/ark:/67375/JVR-CD3LRKVK-P
{{label}}
{{#each values }} {{! loop through ConceptPropertyValue objects }}
{{#if prefLabel }}
{{/if}}
{{/each}}
{{#if notation }}{{ notation }} {{/if}}{{ prefLabel }}
{{#ifDifferentLabelLang lang }} ({{ lang }}){{/ifDifferentLabelLang}}
{{#if vocabName }}
{{ vocabName }}
{{/if}}